Skip to content

Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02546583
Enrollment
458
Registered
2015-09-11
Start date
2015-08-31
Completion date
2020-01-23
Last updated
2025-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Brief summary

Effective diuresis is the primary goal of most acute decompensated heart failure hospitalizations, but diuretic resistance is common and our ability to detect it is limited. Further, there are therapeutically distinct groups of diuretic-resistant patients. These are not easily distinguished using currently available methods, leading to trial-and-error based treatment that promotes lengthy hospitalizations. The aims of this study are: 1. To develop inexpensive and efficient tools to predict diuretic response 2. To understand the prevalence of therapeutically targetable mechanisms of diuretic resistance using endogenous lithium clearance 3. To develop methodology to differentiate diuretic resistance mechanisms using common/inexpensive laboratory tests 4. To provide proof of concept that mechanistically tailored diuretic therapy can improve natriuresis

Detailed description

This study is a minimal-risk observational open-label single center study with randomization between two standard of care interventions. Approximately 500 patients admitted to the hospital (Yale New Haven Health System) with a clinical diagnosis of heart failure will be enrolled in the overall study. Patients will undergo sampling of their blood and collection of urine at a minimum of 4 timepoints (called visits), or a minimum of 5 in the interventional arm. Patients with a low urine sodium output (\<100 mmol) on Visit 1 will be eligible for 1:1 randomization to either an increased dose of their Visit 1 loop diuretic or addition of IV chlorothiazide to their Visit 1 loop diuretic.

Interventions

DRUGIncreased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)

An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).

DRUGIV Chlorothiazide

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

For all patients: Inclusion criteria: * Age ≥ 18 years * Clinical diagnosis of ADHF with at least one objective sign of volume overload: rales, edema, elevated JVP, preadmission weight gain * Current use of bolus IV loop diuretic therapy and projected need by the treating clinician for continued treatment with IV diuretics for at least 3 days with the goal of significant fluid removal (\>1L net fluid loss/day)

Exclusion criteria

* Inability to perform informed consent or comply with the serial urine collection procedures * Significant bladder dysfunction or urinary incontinence * Hematocrit less than 21% or active bleeding For patients in the interventional arm: Inclusion criteria: * Cumulative 6-hour sodium output \< 100 mmol following Visit 1 IV loop diuretic dose * Visit 1 IV loop diuretic dose ≤ 160 mg of furosemide equivalents * Serum sodium \> 125 mmol/L * At least 6 hours since last dose of diuretic

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of sodium prediction equation in predicting suboptimal natriuretic response to a dose of diuretics6 hoursSuboptimal Natriuretic Response is defined as a measured sodium output of \<100 mmol in the 6 hours following the dose of diuretic
Prevalence of mechanistic sub types of Diuretic Resistance (DR) as defined by cutoff values of change in fractional excretion of lithium6 hoursDescriptions of the prevalence of the DR mechanisms at the different time points in the study will be reported.
Accuracy of prediction of mechanistic sub types of DR using universally available laboratory tests6 hoursThe relationship between the change in fractional excretion of potassium and sodium and the change in fractional excretion of endogenous lithium will be assessed in order to develop methodology to identify the etiology of DR using universally available laboratory tests.
Change in total 6-hour sodium output between observational and randomized intervention study days, compared between intervention groups6 hoursSodium output in response to a dose of diuretics will be measured via urine collection.

Secondary

MeasureTime frameDescription
Prediction of mechanistic sub types of DR6 hoursRelationship between the fractional excretion of magnesium or calcium with the fractional excretion of endogenous lithium will also be assessed

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026